The North America SGLT2 inhibitors market size is expected to reach USD 16.37 billion by 2034, exhibiting a CAGR of 8.4% during 2025–2034.
The SGLT2 inhibitors market in North America is experiencing significant growth due to the increasing prevalence of type 2 diabetes, the rising awareness about diabetes management, and the expanding usage of SGLT2 inhibitors for cardiovascular and renal diseases. SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2 protein in the kidneys, which leads to the excretion of excess glucose in the urine, lowering blood sugar levels.
Market Growth Drivers
- Rising Prevalence of Type 2 Diabetes Type 2 diabetes is one of the most common chronic diseases in North America, particularly in the United States and Canada. As obesity rates continue to rise, the prevalence of diabetes is expected to increase, fueling demand for effective treatments. SGLT2 inhibitors are becoming a first-line treatment option for many patients with type 2 diabetes.
- Expanded Indications Beyond Type 2 Diabetes Initially approved for the treatment of type 2 diabetes, SGLT2 inhibitors are now being used for heart failure and chronic kidney disease. Studies have shown that these drugs can reduce the risk of hospitalization due to heart failure and slow the progression of kidney disease, making them highly attractive for managing multiple comorbid conditions. This expanded indication is driving market growth.
- Increasing Awareness and Early Diagnosis of Diabetes as awareness about the risks of type 2 diabetes and its complications increases, early diagnosis and proactive treatment strategies are being adopted. The early intervention with medications like SGLT2 inhibitors contributes to better long-term management of the disease, which is contributing to market expansion.
Download Free Sample PDF Copy of the Report:
Key Companies in North America SGLT2 Inhibitors Market
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Sanofi
- Pfizer Inc.
Key Trends in the Market
- Combination Therapies The trend of combining SGLT2 inhibitors with other classes of diabetes medications, such as GLP-1 receptor agonists and metformin, is gaining momentum. These combination therapies not only improve glycemic control but also offer additional benefits in weight loss and cardiovascular risk reduction, making them more attractive to patients and healthcare providers.
- Shift Toward Personalized Medicine There is a growing emphasis on personalized treatment plans in the management of diabetes. SGLT2 inhibitors are being incorporated into personalized treatment regimens based on patients’ comorbid conditions, such as cardiovascular disease and kidney dysfunction, to optimize clinical outcomes.
- Regenerative Medicine and New Drug Development Research into the potential of regenerative medicine and new drug classes to complement SGLT2 inhibitors is underway. This includes exploring the combination of SGLT2 inhibitors with other emerging therapies aimed at treating diabetic complications and improving overall patient outcomes.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
By Indication Outlook (Revenue – USD Billion, 2020–2034)
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others
By Drug Outlook (Revenue – USD Billion, 2020–2034)
- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
North America SGLT2 Inhibitors Industry Developments
In December 2023, Boehringer Ingelheim received European Commission approval for Jardiance (empagliflozin) 10mg and 25mg tablets to be used as an adjunct to diet and exercise for the treatment of inadequately controlled type 2 diabetes mellitus in children aged ten years and older in the European Union.
In September 2023, Eli Lilly and Company and Boehringer Ingelheim International GmbH announced that the US FDA had approved Jardiance (empagliflozin) for its efficacy in reducing the risk of cardiovascular mortality and hospitalization for heart failure in patients affected by chronic kidney disease.
The North American SGLT2 inhibitors market is poised for strong growth driven by the increasing prevalence of type 2 diabetes, the expanding use of these drugs for cardiovascular and renal disease management, and the availability of new drug formulations and combination therapies. While challenges such as high costs and safety concerns remain, the market’s future looks promising, with ongoing research and development likely to unlock new therapeutic indications and improve patient outcomes.